• Contemporary ClinicContemporary Clinic
  • OTC GuideOTC Guide
  • Pharmacy Times
  • PTCEPTCE
  • Pharmacist Moms GroupPharmacist Moms Group
News
All News
FDA Updates
Press Releases
Media
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conferences
Conference Coverage
Conference Listing
Publications
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
Clinical
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Events
Upcoming Events
Upcoming Webinars
CE
Resources
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
logo
Spotlight
Community/RetailHospitalOncologyPharmacy TechnicianStudent
Clinical Role
Community/RetailHospitalOncologyPharmacy TechnicianSpecialty PharmacyStudent
Clinical
CoronavirusBrain HealthCardiovascular HealthDermatologyDiabetesFluHeart FailureHepatitis/MASHImmunizationMigrainePneumococcalVitamins and Supplements
Supplement Spotlight
October 2023 Pharmacy Technician Edition
All News
FDA Updates
Press Releases
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conference Coverage
Conference Listing
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Upcoming Events
Upcoming Webinars
CE
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
Advertisement

CLINICAL ROLE -

Community/Retail
| Hospital
| Oncology
| Pharmacy Technician
| Student

News

Article

November 20, 2023

Telemedicine Shows Increase in Curing Hepatitis C Virus Related to Opioid Use Disorder

Author(s):

Ashley Gallagher, Editor

The results suggest that telemedicine could be used to help improve access for other populations that might be stigmatized, beyond hepatitis C virus and opioid use disorder.

Telemedicine is more effective for treating and curing hepatitis C virus (HCV) for individuals with opioid use disorder (OUD) compared to usual care, according to results of a treatment program by individuals from the University at Buffalo. The findings, presented at the American Association for the Study of Liver Diseases, also demonstrated that the advantages of being cured impacted sustainable health and social benefits.

Macro of oxycodone opioid tablets | Image Credit: steheap - stock.adobe.com

steheap - stock.adobe.com

According to a press release, there have been few randomized controlled trials to determine the effectiveness of telemedicine in those who are underserved, including those with OUD and HCV. The investigators aimed to determine the effectiveness in telemedicine for an opioid treatment program for HCV management, which would remove the need for offsite referrals, according to the investigators. The program was supported by an $8.2 million award from the Patient-Centered Outcomes Research Institute as well as more than $3 million from the Troup Fund of the Kaleida Health Foundation.

Investigators compared the onsite-facilitated telemedicine to offsite referrals with a specialist in HCV, which is the usual care for treating the virus. The telemedicine visits were facilitated by a case manager, who was an educator and patient advocate. The study was conducted at 12 opioid treatment programs in New York State from 2017 to 2022. The treatment programs also dispensed methadone, enrolling 602 individuals with OUD and HCV. The individuals received treatment with direct acting antiviral medications for HCV. Investigators followed the individuals for 2 years after being cured and evaluated them for reinfection, according to the press release.

The results showed that 90.7% of participants in the telemedicine arm were cured of HCV infection compared to 35.2% of individuals who were referred to an offsite specialist. Additionally, investigators found that approximately two-thirds of those in the referral arm did not initiate HCV treatment. In the follow up, investigators reported minimal HCV reinfections.

Furthermore, being cured of HCV also demonstrated subsequent health and well-being of individuals, including reductions in substance use. This was true for either arm, as long as the individual was cured. According to Andrew H. Talal, MD, professor of medicine in the Jacobs School of Medicine and Biomedical Sciences at the University of Buffalo, interviews with the patients also showed that being cured of HCV improved self-confidence, helping the individuals address other health issues and challenges.

Furthermore, investigators reported that in many cases after treatment for OUD was initiated and HCV was cured, individuals were able to successfully seek employment, improve education, and reduce activity within the criminal justice system.

“Our study demonstrates how telemedicine successfully integrates medical and behavioral treatment,” Talal said in the press release. “Our participants viewed the opioid treatment program as a destigmatizing environment to begin with. When participants trust the staff in the program, that trust then extends to the telemedicine provider, especially when they express empathy. These attributes allow for successful HCV treatment and lead to high patient satisfaction through telemedicine.”

Talal added that telemedicine should be further investigated to increase health care access for other underserved populations with other health conditions. One of the key benefits of telemedicine was its ability to improve access for those with OUD who typically encounter stigma in other health care setting. Telemedicine could be used to help improve access to other type of care for other populations that might be stigmatized.

Reference

PCORI study: telemedicine treatment for HCV in people with opioid use disorder was more than twice as successful as offsite referral. News release. EurekAlert. November 10, 2023. Accessed November 14, 2023. https://www.eurekalert.org/news-releases/1007723

Related Videos
Image credit: Dr_Microbe | stock.adobe.com
Image credit: K KStock | stock.adobe.com
Image credit: komokvm | stock.adobe.com
Vial of Pneumococcal vaccine - Image credit: Bernard Chantal | stock.adobe.com
Related Content
Advertisement
NLA 2025: Data on ApoC3 Inhibitors Shows Promise Across a Spectrum of Hypertriglyceridemic Disorders
May 31st 2025

NLA 2025: Data on ApoC3 Inhibitors Shows Promise Across a Spectrum of Hypertriglyceridemic Disorders

Alana Hippensteele, Lead Editor
Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings
May 28th 2025

Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings

Alexandra Gerlach, Associate Editor
Illustration of myocardial infarction
May 30th 2025

NLA 2025: Inclisiran With Standard Care Provides Rapid, Sustained Lowering of LDL-C in Patients With Recent Acute Coronary Syndrome

Luke Halpern, Assistant Editor
Pharmacy Focus: Navigating Seasonal Allergies
May 28th 2025

Pharmacy Focus: Navigating Seasonal Allergies

Luke Halpern, Assistant Editor Derek Webb, PharmD
Woman can't eat bread and grain products because of gluten intolerance. A young celiac woman suffers from abdominal pain after eating fresh bread - Image credit: weyo | stock.adobe.com
May 30th 2025

FDA Grants Fast Track Designation to Drug Candidate for Celiac Disease

Kennedy Ferruggia, Assistant Editor
Washington, DC, USA - June 24, 2022: The symbol of the U.S. Department of Health and Human Services is seen at the entrance to its headquarters in the Hubert H. Humphrey Building in Washington, DC
May 30th 2025

HHS Cancels Millions in Pandemic Influenza mRNA Vaccine Development Grants

Luke Halpern, Assistant Editor
Related Content
Advertisement
NLA 2025: Data on ApoC3 Inhibitors Shows Promise Across a Spectrum of Hypertriglyceridemic Disorders
May 31st 2025

NLA 2025: Data on ApoC3 Inhibitors Shows Promise Across a Spectrum of Hypertriglyceridemic Disorders

Alana Hippensteele, Lead Editor
Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings
May 28th 2025

Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings

Alexandra Gerlach, Associate Editor
Illustration of myocardial infarction
May 30th 2025

NLA 2025: Inclisiran With Standard Care Provides Rapid, Sustained Lowering of LDL-C in Patients With Recent Acute Coronary Syndrome

Luke Halpern, Assistant Editor
Pharmacy Focus: Navigating Seasonal Allergies
May 28th 2025

Pharmacy Focus: Navigating Seasonal Allergies

Luke Halpern, Assistant Editor Derek Webb, PharmD
Woman can't eat bread and grain products because of gluten intolerance. A young celiac woman suffers from abdominal pain after eating fresh bread - Image credit: weyo | stock.adobe.com
May 30th 2025

FDA Grants Fast Track Designation to Drug Candidate for Celiac Disease

Kennedy Ferruggia, Assistant Editor
Washington, DC, USA - June 24, 2022: The symbol of the U.S. Department of Health and Human Services is seen at the entrance to its headquarters in the Hubert H. Humphrey Building in Washington, DC
May 30th 2025

HHS Cancels Millions in Pandemic Influenza mRNA Vaccine Development Grants

Luke Halpern, Assistant Editor
Consent Preferences
About Us
Clinical Forums
Advertise
Contact Us
Editorial Staff
Privacy Policy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

Download on Apple
© 2025 MJH Life Sciences

All rights reserved.